ClinicalTrials.gg

Program

flortaucipir

Also written as “Flortaucipir F18”, “[18F]Flortaucipir Injection” and “flortaucipir F 18”.

Its studies are mostly in Alzheimer Disease · Cognitive Dysfunction · Frontotemporal Dementia · Chronic Traumatic Encephalopathy · Supranuclear Palsy, Progressive, led by 2 companies.

Furthest: phase 3, since Dec 16, 201321 company-led studies, 1 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly200 open or runningphase 3since Dec 16, 2013Nov 8, 2013none ahead
Eli Radiopharma11 open or runningphase 1since Apr 26, 2026Apr 26, 2026Dec 31, 2026phase 1 · NCT07580703

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Nov 8, 2013.

  1. Oct 28, 2014Phase 2 study in Alzheimer DiseaseEli Lilly · NCT02278367 · 179 enrolled · United States
  2. Oct 28, 2014Phase 1 study in Alzheimer DiseaseEli Lilly · NCT02278354 · 35 enrolled · United States
  3. Jan 8, 20152 phase 1 studies in Alzheimer DiseaseEli Lilly · NCT02350634, NCT02336360
  4. Jul 28, 2015Phase 1 study in Brain Injuries, TraumaticEli Lilly · NCT02512029 · United States
  5. Aug 3, 2015Phase 3 study in Alzheimer DiseaseEli Lilly · NCT02516046 · 156 enrolled · United States, Australia
  6. Jun 7, 2016Phase 2 study in Alzheimer DiseaseEli Lilly · NCT02795780 · 79 enrolled · United States
  7. Jan 31, 2017Phase 1 study in Frontotemporal DementiaEli Lilly · NCT03040713 · 16 enrolled · United States
  8. Feb 10, 2017Phase 1 study in Cognitive DysfunctionEli Lilly · NCT03052972 · 23 enrolled · United States
  9. Oct 16, 2017Phase 2 study in Alzheimer DiseaseEli Lilly · NCT03322462 · 155 enrolled · United States, Canada
  10. Mar 8, 2018Phase 2 study in Alzheimer DiseaseEli Lilly · NCT03467477 · 161 enrolled · United States
  11. Mar 27, 20192 phase 3 studies in Alzheimer DiseaseEli Lilly · NCT03901092, NCT03901105
  12. Jul 8, 2020Early phase 1 study in Alzheimer DiseaseEli Lilly · NCT04474405 · 36 enrolled · United States
  13. Jul 8, 2020Phase 1 study in Alzheimer DiseaseEli Lilly · NCT04468347 · 89 enrolled
  14. Apr 26, 2026Eli Radiopharma's first study: phase 1 study in Alzheimer DiseaseNew to Eli RadiopharmaEli Radiopharma · NCT07580703 · 18 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in Alzheimer DiseaseEli Radiopharma · NCT07580703

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 21 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07580703Alzheimer Disease · China1RecruitingEli RadiopharmaDec 31, 202618
NCT04474405Alzheimer Disease · United StatesEarly 1CompletedEli LillyDec 9, 201336
NCT04468347Alzheimer Disease1CompletedEli LillyFeb 201889
NCT03901105Alzheimer Disease · United States3CompletedEli LillyApr 28, 2019205
NCT03901092Alzheimer Disease · United States3CompletedEli LillyApr 26, 2019242
NCT03467477Alzheimer Disease · United States2CompletedEli LillyNov 15, 2018161
NCT03322462Alzheimer Disease · United States, Canada2CompletedEli LillyAug 31, 2018155
NCT03052972Cognitive Dysfunction · United States1TerminatedEli LillyAug 14, 201823
NCT03040713Frontotemporal Dementia · United States1CompletedEli LillyOct 24, 201816
NCT02795780Alzheimer Disease · United States2CompletedEli LillyAug 28, 201779
NCT02516046Alzheimer Disease · United States, Australia3CompletedEli LillyJun 13, 2018156
NCT02512029Brain Injuries, Traumatic · United States1WithdrawnEli LillyApr 20170
NCT02350634Alzheimer Disease · United States1CompletedEli LillyJun 16, 20173
NCT02336360Alzheimer Disease · United States1CompletedEli LillyJun 20156
NCT02278367Alzheimer Disease · United States2CompletedEli LillyJun 26, 2019179
NCT02278354Alzheimer Disease · United States1CompletedEli LillyFeb 3, 201735
NCT02167594Supranuclear Palsy, Progressive · United States1CompletedEli LillyJul 11, 201629
NCT02079766Chronic Traumatic Encephalopathy · United States2CompletedEli LillyOct 201541
NCT02051764Alzheimer Disease · United States2TerminatedEli LillyDec 201644
NCT02016560Alzheimer Disease · United States3CompletedEli LillyJul 28, 2017383
NCT01992380Alzheimer Disease · United States1CompletedEli LillyMay 30, 201424

How it is read

Names in the registry

  • “Flortaucipir F18”, 17 entries
  • “[18F]Flortaucipir Injection”, 1 entry
  • “flortaucipir F 18”, 1 entry
  • “flortaucipir F18”, 1 entry
  • “18F-AV-1451”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.